CETP and coronary artery disorder: There has been a heated debate on the role of HDL particles in CAD in recent years following the failure of several trials for CETP inhibitors (Barter et al., 2007; Schwartz et al., 2012; Lincoff et al., 2017) and recombinant ApoA1 (Nicholls et al., 2018) targeting HDL cholesterol.